Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Abstract Background The use of pyronaridine-artesunate (PA) has been associated with scarce transaminitis in patients. This analysis aimed to evaluate the hepatic safety profile of repeated treatment with PA versus artemether–lumefantrine (AL) in patients with consecutive uncomplicated malaria episo...

Full description

Bibliographic Details
Main Authors: Yves Daniel Compaoré, Issaka Zongo, Anyirékun F. Somé, Nouhoun Barry, Frederick Nikiéma, Talato N. Kaboré, Aminata Ouattara, Zachari Kabré, Kadidiatou Wermi, Moussa Zongo, Rakiswende S. Yerbanga, Issaka Sagara, Abdoulaye Djimdé, Jean Bosco Ouédraogo
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Malaria Journal
Subjects:
Repeated treatment
Pyronaridine‐artesunate
Artemether–lumefantrine
Uncomplicated malaria
Hepatoxicity
Hy’s law
Online Access:https://doi.org/10.1186/s12936-021-03593-6

Internet

https://doi.org/10.1186/s12936-021-03593-6

Similar Items